Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00321646
Status:
COMPLETED
Last Update Posted:
2016-05-16
First Post:
2006-05-02
Brief Title:
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
Sponsor:
Mary-Ellen Taplin MD
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
05-438
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Mary-Ellen Taplin MD
Lead Sponsor Class:
OTHER
Responsible Party:
Mary-Ellen Taplin MD
Responsible Party Title:
Assistant Professor of Medicine HMS
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |
| Beth Israel Deaconess Medical Center | OTHER |
| Duke University | OTHER |
| Genentech Inc | INDUSTRY |